Enflicoxib

Postoperative pain is most effectively managed pre-emptively and enflicoxib characteristics make it a good candidate to control it with a single administration. To assess the efficacy of enflicoxib in the control of postoperative pain and inflammation associated with orthopaedic surgery, twenty-eight dogs were randomised to receive 8 mg/kg enflicoxib (n = 14) orally the day before surgery, or 0.2 mg/kg meloxicam (n = 14) subcutaneously at induction and orally at 0.1 mg/kg daily every 24 h for seven days. Veterinarians assessed efficacy with the Glasgow Composite Pain Scale Short-Form (GCPS-SF) at 1.5, 3, 5, 8, 24 and 168 h after surgery. Visual analog scales (VAS) were also used to assess pain at rest, pain at palpation and inflammation. Enflicoxib showed to be non-inferior to meloxicam in the GCPS-SF total scores, at each time point, and the area under the curve (GCPS-SF AUC) for the first 24 h. No differences were observed in VAS scores at any time point after surgery or the global efficacy as assessed by the veterinarians, or the dog's wellbeing assessed by the owners. Enflicoxib administered 24 h before surgery is efficacious and safe for the control of postoperative pain associated with orthopaedic surgery. One single dose would control postoperative pain and inflammation for one whole week. The results need further confirmation in larger sample size studies.

Pyrazolines are a significant class of heterocyclic compounds with essential biological activities. They are quite stable, which has inspired medicinal chemists to experiment with the ring's structure in many different ways to create a variety of pharmacological activities. The structures of numerous commercially available therapeutic agents contain a pyrazoline ring. Pyrazolines are well-known for their ability to treat neurodegenerative diseases. The neurodegenerative diseases that affect huge populations globally include Alzheimer's disease (AD), Parkinson's disease (PD), and psychiatric disorders. The neuroprotective properties of pyrazolines published since 2003 are covered in the current review. Structure-activity relationships (SARs), molecular docking simulation, anticholinesterase (anti-AChE), and monoamine oxidase (MAO A/B) inhibitory actions are all covered in this article. Pyrazolines were discovered to have beneficial effects in the management of AD and were revealed to be inhibitors of acetylcholine esterase (AChE) and beta-amyloid (A_β) plaques. They were discovered to be efficient against PD and also targeted MAO B and COMT. It was discovered that the pyrazolines block MAO A to treat psychiatric diseases. Pyrazolines are significant heteroaromatic scaffolds with a variety of biological functions. They were discovered to be remarkably stable and serve as an indispensable anchor for the development of new drugs. By blocking AChE and MAOs, they may be used to treat neurodegenerative diseases. The discussion outlined here is an essential and helpful resource for medicinal chemists who are investigating and applying pyrazolines in neurodegenerative research initiatives as well as to expedite future research programs on neurodegenerative disorders.